skip to content

Department of Pathology

 

Biography

Suzanne obtained her PhD from the world-renowned Paterson Institute for Cancer Research and the Christie Hospital in Manchester where she examined the potential toxic side-effects of chemoprotective gene therapy. This work was a collaborative effort with what was at that time the AstraZeneca Central Toxicology Labs at Alderley Edge.
Following this training period Suzanne moved to a research post at the Babraham Institute in Cambridge where under the guidance of Dr Denis Alexander she began to investigate mechanisms of Lymphomagenesis, a subject that she has pursued to become a world-expert in paediatric lymphomas, specifically Anaplastic Large Cell Lymphoma (ALCL). Since 2005, Suzanne has been leading an academic research group at the University of Cambridge within the Department of Pathology and based at the Addenbrooke’s Hospital campus in Cambridge. It is here that Suzanne conducts academic research of an international standard and also teaches and examines aspects of the medical, veterinary and natural science tripos. Suzanne is also the director of postgraduate education in the Department of Pathology.

In 2007, Suzanne was awarded the prestigious Leukaemia and Lymphoma Research (LLR; now Blood Cancer UK) Bennett Fellowship and in 2012 a further 5-year LLR senior lectureship award. Amongst her achievements are the inception and establishment of the European Research Initiative on ALCL, a study group that brings together scientists from across Europe to foster collaboration and advancement in this important area of health research. Suzanne was also the lead of ‘ALKATRAS’, a European Union Marie Curie Innovative Training Network of 14 research groups in 7 EU countries and is currently non-clinical chair of the European Inter-Group for Collaboration into Childhood Non-Hodgkin Lymphoma (EICNHL), co-chair of the Cancer Research UK (CRUK) Cambridge Centre Paediatric Programme and biological lead for the National Cancer Research Institute (NCRI) paediatric lymphoma Clinical Study Group (CSG). Suzanne collaborates with a wide array of scientists and labs around the world, most notably the Uganda Cancer Institute in Kampala with whom she is working towards finding better therapies for children with cancer.

Amongst her other interests Suzanne is the scientific advisor to the Alex Hulme Foundation and Francesca Richardson Trust. She is also a member of both the American and British Associations for Cancer Research (BACR/AACR), the Children’s Cancer and Leukaemia Group (CCLG) in the UK and the International Society for Paediatric Oncology (SIOP). Suzanne also sits on the scientific committee of the European arm of SIOP, the MHRA plastics, reconstructive and aesthetic surgery (PRASEAG) committee and the European Commission’s Scientific committee on Health, Environmental and Emerging Risks (SCHEER) working group on breast implants and cancer. In addition, she is a member of the international grant review panels of the World Cancer Research Fund and the Swedish Research Council’s medicine and health review panel.

Research

Turner Research

In our lab, we investigate the pathogenesis and aetiology of paediatric cancers towards the development of biomarkers to facilitate kinder, less toxic and novel therapeutic approaches.

Mechanisms of Lymphomagenesis

Lymphoma is a heterogeneous disease class consisting of greater than 40 different sub-types and the incidence of this disease has been increasing year on year. In our research we are making progress towards understanding how and why lymphoma develops and hence in the development of new treatments. We investigate a paradigm of lymphomageneis in which a chromosomal translocation leads to the generation of an oncogene and subsequent presumed transformation of T-cells. The oncogene we work with is Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a hyperactive tyrosine kinase generated as a result of a translocation between chromosomes 2 and 5. This event is associated with greater than 90% of cases diagnosed as anaplastic large cell lymphoma (ALCL), a mature T-cell malignancy mainly occurring in paediatric patients. Our research aims to unravel the events leading from the t(2;5) to lymphoma. We use a variety of experimental approaches to reach this goal.

Understanding drug resistance in paediatric cancers

We are also developing a resource of patient derived xenografts of paediatric lymphoma, specifically ALCL and Burkitt lymphoma as well as neuroblastoma. Applying these models, our lab is conducting research to experimentally-induce relapse in an effort to understand clonal evolution of tumour cell growth. With this knowledge in hand, our lab then applies high-throughput drug screens and sequencing approaches to develop novel therapeutic regimens. Alongside, this research activity, we also employ CRISPR/Cas9 screens for the identification of putative mechanisms of drug resistance employing cell lines.

Comparative analysis of endemic and sporadic Burkitt lymphoma

Our lab works together with Jackson Orem at the Uganda Cancer Institute in Kampala, Uganda in an effort to understand the aetiology and pathogenesis of Burkitt lymphoma with a particular emphasis on tumour clonal evolution with treatment. This aspect of our research is supported by Cambridge Africa.

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)

The most recent addition to the family of ALCL is a form of cancer associated with the presence of textured breast implants. Given our 20 years of experience of working towards understanding the pathogenesis of ALCL, we have turned our attention to unraveling the mechanisms that drive this specific form of cancer.

Group Members:

  • Jamie Matthews 
  • Mun Liew
  • Perla Pucci
  • Lucy Hare
  • Emily James
  • Gill Currie
  • Chris Steele
  • Leila Jahangiri
  • We collaborate with Dr Amos Burke, a paediatric oncologist at Addenbrooke's hospital in Cambridge

Publications

Key publications: 

A full list of publications can be found via ORCID ID: https://orcid.org/0000-0002-8439-4507

  1. Garland, G.D*., Ducray, S.P*., Jahangiri, L.J., Pucci, P., Burke, G.A.A., Monahan, J., Lai, R., Merkel, O., Schiefer, A., Kenner, L., Bannister, A.J. and Turner, S.D. (2022) BRG1 and NPM-ALK are co-regulated in Anaplastic Large Cell Lymphoma; BRG1 is a potential therapeutic target in ALCL. Cancers, in press
  2. Lucy Hare, G.A. Amos Burke and Suzanne D. Turner (2021) Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL 13(23), 6003; https://doi.org/10.3390/cancers13236003
  3. Karaca-Atabay, E., Wang, Q., Cheong, T., Ambrogio, C., Mota, I., Prokoph, N., Leonardi, N., Hossa, J., Patrucco, E., Pich, A., Mologni, L., Gambacorti-Passerini, C., Brugières, L., Geoerger, B., Turner, S.D., Voena, C., & Chiarle, R. (2021) Tyrosine phosphatases regulate resistance to ALK inhibitors in lymphoma. Blood, in press
  4. Newman, A.M., Zaka, M., Zhou, P., Blain, A.E., Erhorn, A., Barnard, A., Crossland, R.E., Wilkinson, S., Enshaei, A., De Zordi, J., Harding, F., Taj, M., Wood, K., Televantou, D., Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma, Leukemia, in press
  5. Gong, C., Krupka, J., Gao, J., Grigoropoulos, N.F., Screen, M., Cucco, F., Mohammed, M., Usheva, Z., Bornelöv, S., Ruiz De Los Mozos, I., Meng, W., Barrans, S., Bain, A., Burke, G.A., Forde, S., Matthews, J.D., Beer, P., Cooke, S., Burton, C., Campbell, P., Davies, A., Roman, E., Turner, S.D., Ule, J., Rand, V., Oellerich, T., Turner, M., Du, M., Samarajiwa, S. and Hodson, D.J. (2021) DDX3X and DDX3Y co-operate to facilitate MYC-driven B cell lymphomas. Molecular Cell, in press
  6. Liang, H-C., Costanza, M., Prutsch, N., Zimmerman, M., Gurnhofer, E., Montes-Mojarro, I.A., Abraham, B.J., Prokoph, N., Stoiber, S., Tangermann, S., Lobello, C., Oppelt, J., Anagnostopoulos, I., Hielscher, T., Pervez, S., Klapper, W., Zammarchi, F., Silva, D.A., Garcia, K.C., Baker, D., Janz, M., Schleussner, N., Fend, F., Pospíšilová, S., Wallwitz, J., Stoiber, D., Simonitsch-Klupp, I., Cerroni, L., Pileri, S., de Leval, L., Sibon, D., Fataccioli, V., Gaulard, P., Assaf, C., Knörr, F., Damm-Welk, C., Woessmann, W., Turner, S.D., Look, A.T., Mathas, S*., Kenner, L*. and Merkel, O*. (2021) Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma. Nature Communications, in press
  7. Ulferts, R., Marcassa, E., Timimi, L., Lee, L., Daley, A., Montaner, B., Turner, S.D., Florey, O., Baillie, K., Beale, R. (2021). Subtractive CRISPR screen identifies factors involved in non-canonical LC3 lipidation. BioRXIV Cell Reports, In press
  8. Sangiorgio, V.F., Ruiz-Cordero, R., Vega, F.,  Feldman, A.L., Becker-Hecker, R., Evans, M.G., Clemens, M.W., Magno, W.B., Harris, H.L., Sohani, A., Sieling, B.A., Johnson, L., Macneill, F., O'donoghue, J., Patani, N., Televantou, D., Turner, S.D., Wotherspoon A., Young, K.H., Medeiros, L.J., and Miranda, R.N. (2021) EBV-Positive Lymphomas in Patients with Breast Implants: Another Subgroup with a Possible Etiologic Relationship to Breast Implants? Modern Pathology, doi: 10.1038/s41379-021-00863-1
  9. Taj, M.M., Maecker-Kolhoff, B., Ling, R., Bomken, S., Burkhardt, B., Chiang, A.K.S., Csoka, M., Füreder, A., Haouy, S., Lazic, J., Miakova, N., Minard-Colin, V., Turner, S.D., Uyttebroeck, A. and Attarbaschi, A. on behalf of the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the international Berlin-Frankfurt-Münster (i-BFM) Study Group (2021). Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome of 25 paediatric patients. British Journal of Haematology Jun;193(6):1178-1184. doi: 10.1111/bjh.17398
  10. Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams DM, Burke GAA, Horibe K, Nakagawa A, Wrobel G, Mann G, Csoka M, Uyttebroeck A, Delgado RF, Beishuizen A, Mellgren K, Burkhardt B, Klapper W, Turner SD, d’Amore ESG1, Lamant L, Reiter A, Woessmann W, Brugieres L, Pillon M, on behalf of the European Inter-Group for Childhood Non-Hodgkin lymphoma (EICNHL). (2020) Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Updated Long Term Results of the International ALCL99 Trial. Cancers 12(10):2747. doi: 10.3390/cancers12102747.
  11. Aksoy, O., Pencik, J., Hartenbach, M., Moazzami, A.A.,  Schlederer, M., Balber, T., Varady, A., Philippe, C., Baltzer, P., Mazumder, B., Mazumder, B., Whitchurch, J.B., Roberts, C.J., Haitel, A., Herac, M., Susani, M., Mitterhauser, M., Marculescu, R., Strangl-Kremser, J., Hassler, M., Kramer, G., Shariat, S.F., Turner, S.D., Tichy, B., Oppelt, J., Pospisilova, S., Hartenbach, S., Tangermann, S., Egger, G., Neubauer, H.A., Moriggl, R., Culig, Z., Greiner, G., Hoermann, G., Hacker, M., Heery, D.M., Merkel, O. and Kenner, L. (2020) Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer. International Journal of Cancer, 148(3):731-747 (published in 2019 as a preprint BioRCiv doi: https://doi.org/10.1101/2019.12.19.881151)
  12. Wim H. De Jong, Demosthenes Panagiotakos, Ana Proykova, Theodoros Samaras, Mark W. Clemens, Daphne De Jong, Ingrid Hopper, Hinne A. Rakhorst, Fabio Santanelli di Pompeo, Suzanne D. Turner; on behalf of SCHEER (2021) Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: report of the Scientific Committee on Health, Emerging and Environmental Risks (SCHEER). Regulatory Toxicology and Pharmacology, Jun 30;125:104982. doi: 10.1016/j.yrtph.2021.104982
  13. Leila Jahangiri, Tala Ishola, Perla Pucci, Ricky M. Trigg, Joao Pereira, John A. Williams, Megan L. Cavanagh, Georgios V. Gkoutos, Loukia Tsaprouni and Suzanne D. Turner (2021) The Role of Autophagy and lncRNAs in the Maintenance of Cancer Stem Cells. Cancers 13(6), 1239; https://doi.org/10.3390/cancers13061239
  14. Turton, P., El-Sharkawi, D., Lyburn, I., Sharma, B., Mahalingam, P., Turner, S.D., MacNeil, F., Johnson, L., Hamilton, S., Burton, C. and Mercer, N. (2020) UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG). European Journal of Surgical Oncology Feb;47(2):199-210. doi: 10.1016/j.ejso.2020.07.043, co-publication in British Journal of Haematology Feb;192(3):444-458. doi: 10.1111/bjh.17194 and Journal of Plastic and Reconstructive Surgery Jan;74(1):13-29. doi: 10.1016/j.bjps.2020.10.064
  15. Okello, C.D., Niyonzima, N., Ferraresso, M., Kadhumbula, S., Ddungu, H., Tarlock, K., Balagadde, J., Omoding, A., Karagu, A., Mwaiselage, J., Harlan, J.M., Uldrick, T.S., Turner, S.D.* and Orem, J.* (2021) Review Series on Priorities in Haematological Care in Sub-Saharan Africa (SSA), Blood Cancers. Haematological Malignancies (HMs) in Sub-Saharan Africa (SSA): East Africa as an exemplar for Improving Care in the Region. Lancet Haematology, In press 
  16. Deva, A.K., Turner, S.D, Kadin, M.E., Magnusson, M.R., Prince, H.M., Miranda, R.N., Inghirami, G.G. and Adams, W.P. (2020) Etiology of Breast Implant–Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. Cancers, Dec 21;12(12):3861. doi: 10.3390/cancers12123861 
  17. Forde, S., Matthews, J.D., Jahangiri, L., Lee, L.C., Malcolm, T.I., Bell, N., Bomken, S., Burke, G.A.A., and Turner, S.D. (2020) Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy, British Journal of Haematology,  http://dx.doi.org/10.1111/bjh.17043 
  18. Prokoph, N., Probst, N.A., Lee, L.C., Monahan, J.M., Malik, V., Liang, H-C., Sharma, G.G., Montes-Mojarro, I., Mota, I., Larose, H., Forde, S.D., Imamoglu, R., Matthews, J.D., Trigg, R., Ceccon, M., Ducray, S.P., Lobello, C., Janikova, A., Gambacorti-Passerini, C., Pospisilova, S., Kenner, L., Klapper, W., Jauch, R., Woessmann, W., Chiarle, R., Mologni, L., Merkel, O., Brugières, L., Geoerger, B., Barbieri, I., and Turner, S.D. (2020) Inflammatory networks drive resistance to drugs in ALCL, ALK+; the IL10R is up-regulated in response to consistent exposure to ALK inhibition. Blood, In press 
  19. Larose, H., Prokoph, N., Mian, S., Nuglozeh, E., Fazaludeen, F.M.S., Elmouna, A., Ashankyty, I., Mologni, L., Gambacorti-Passerini, C., Ming-Qing Du1, Hoefler, G., Pospisilova, S., Woessmann, W., Blundell, T., Ali., Damm-Welk, C., Fedorova, A., Lamant, L., Schlederer, M., Kenner, L., Merkel O. and Turner, S.D (2020) A novel mutation in Notch1 contributes to the pathogenesis of ALCL. Haematologica, in press 
  20. Klingeberg, C., Kreutmair, S., Poggio, T., Keller, A., Andrieux, G., Miething, C., Follo, M., Pfeifer, D., Lengerke, C., Fend, F., Qintanilla de Fend, L., Zeiser, R., Turner, S.D., Boerries, M., Duyster, J. and Illert, A.L. (2019) Existence of reprogrammed lymphoma initiating cells in a murine ALCL model. Leukemia, in press 
  21. Turner, S.D., Inghirami, G.I., Mirando, R.M. and Kadin, M (2019) Cell of origin and immunological events in the pathogenesis of BIA-ALCL. American Journal of Pathology, doi: 10.1016/j.ajpath.2019.09.005 
  22. Trigg, R.M., Shaw, J.A. and Turner, S.D. (2019) Opportunities and challenges of circulating biomarkers in neuroblastoma. Open Biology, 9(5):190056. doi: 10.1098/rsob.190056 
  23. Fritzal, F., Turner, S.D.* and Kenner, L.* (2019) Is Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) a Hazard of Breast Implant Surgery? Open Biology, 9(4):190006. doi: 10.1098/rsob.190006 
  24. Larose, H., Burke, G.A.A., Lowe, E. and Turner, S.D. (2019) From Bench to Bedside: The past, present and future of therapy for systemic paediatric ALCL, ALK+ British Journal of Haematology, doi: 10.1111/bjh.15763. 
  25. Trigg, R.M.,* Lee, L.C.,* Prokoph, N.,* Jahangiri, L., Reynolds C.P., Burke, G.A.A., Probst, N.A., Han, M., Matthews, J.D., Lim, K.K., Manners, E., Martinez, S., Pastor, J., Blanco-Aparicio, C., Merkel, O., Garces de los Fayos Alonso, I., Kodajova, P., Tangermann, S., Högler, S., Luo, J., Kenner, L.* and Turner, S.D.* (2019) PIM1 inhibition enhances the sensitivity of high-risk aberrant  1 ALK-expressing neuroblastoma to ALK inhibition regardless of MYCN status. Nature Communications, DOI: 10.1038/s41467-019-13315-x
  26. This publication was highlighted as an ‘editor’s choice’ in Science Translational Medicine: Joan Montero, (2019) A new hope for neuroblastoma treatment? Science Translational Medicine 11, 523, eaaz9769 DOI: 10.1126/scitranslmed.aaz9769
  27. Haque, M., Li,J., Huang, Y-H., Almowaled, M., Barger, C.J., Karpf,A.R., Wang, P., Chen, W., Turner, S.D. and Lai, R. (2019) NPM-ALK is a key regulator of the oncoprotein FOXM1 in ALK-positive anaplastic large cell lymphoma: identification of a novel role for NPM1 in the pathobiology of NPM-ALK. Cancers, 11(8). pii: E1119. doi: 10.3390/cancers11081119
  28. Prutsch, N., Suske, T., Liang, H.C., Wu, L., Simonitsch- Klupp, I., Alvarez-Hernandez, A., Gurnhofer, E., Schlederer, M., Roos, S., Kornauth, C., Leone, D., Aufinger, A., Hielscher, T., Aberger, F., Stoiber, D., Strobl, B., Müller, M., Jäger, U., Staber, P., Grebien, F., Moriggl, R., Inghirami, G., Sanda, T., Look, A.T., Turner, S.D., Kenner, L. and Merkel, O. (2018) Dependency on the TYK2/STAT1/MCL1 axis in Anaplastic Large Cell Lymphoma. Leukemia Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. 
  29. Schleussner, N., Merkel, O., Hummel, F., Costanza, M., Huan-Chang Liang, H-C., Romagnani, C., Durek, P., Anagnostopoulos, I., Hummel, M., Jöhrens, K., Niedobitek., A, Griffin, P.R., Woessmann, W., Damm-Welk, C., Hinze, C., Stoiber, D., Gillissen, B., Turner, S.D., Kaergel, E., von Hoff, L., Grau, M., Lenz, G., Dörken, B., Scheidereit, C., Kenner, L., Janz, M., and Mathas, S. (2017) The AP-1 -BATF and -BATF3 module is essential for growth, survival and TH17 / ILC3 skewing of anaplastic large cell lymphoma. Leukemia 32: 1994–2007 doi: 10.1038/s41375-018-0045-9 
  30. Johnson, L., O’Donoghue, J.M., McLean, N., Turton, P., Khan, A.A., Turner, S.D., Lennard, A., Collis, N., Butterworth, M., Gui, G., Bristol, J., Hurren, J., Smith, S., Grover, K., Spyrou, G., Krupa, K., Azmy, I.A., Young, I.E., Staiano, H., Khalil J.J., and MacNeill, F.A. (2017) Breast Implant Associated Anaplastic Large Cell Lymphoma: The UK experience. Recommendations on its management and implications for informed consent. European Journal of Surgical Oncology Aug;43(8):1393-1401. doi: 10.1016/j.ejso.2017.05.004 
  31. Hassler, M.R., Pulverer, W., Redl, E., Hacker, J., Garland, G., Schiefer, A., Simonitsch-Klupp, I., Kenner, L., Weinhäusel, A., Turner, S.D. and Egger, G. (2016) ALK-dependent transcription factor networks are associated with epigenomic alterations of DNA methylation in ALCL. Cell Reports 17(2):596-608. doi: 10.1016/j.celrep.2016.09.018 
  32. Damm-Welk C., Fischer M., Narayanan V, Camidge R., Harris M., Siddiqi F., Burke G.A.A., Lehrnbecher T., Pulford K., Oschlies I., Siebert R., Turner SD* and Woessmann W*. (2016) Anti-ALK-antibodies in patients with ALK-positive malignancies not expressing NPM-ALK. Journal of Cancer, 7(11): 1383-1387. 
  33. Malcolm, T., Hodson, D.J., Macintrye E.A. and Turner, S.D. (2016) Challenging perspectives on the cellular origin of lymphoma. Open Biology, 6(9). pii: 160232 
  34. Malcolm, T*., Villarese, P*., Fairbairn, C., Lamant, L., Trinquand, A., Hook, C.E., Burke, G.A.A., Brugieres, L., Hughes K., Payet, D., Merkel, O., Schiefer, A., Ashankyty, I., Mian, S., Wasik, M., Turner, M., Kenner, L., Asnafi, V., Macintyre, E. and Turner, S.D. (2016) NPM-ALK mimics beta selection enabling thymic escape and peripheral lymphoma development. Nature Communications, 7, Article number: 10087 doi:10.1038/ncomms10087
  35. Ceccon M., Boggio Merlo E., Mologni L., Poggio T., Varesio L.M., Menotti M., Bombelli S., Rigolio R., Manazza A.D., Ambrogio C., Giudici G., Casati C., Mastini C.,  Compagno M., Turner S.D., Gambacorti-Passerini C., Voena C. and Chiarle R. (2015) Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene, doi: 10.1038/onc.2015.456 
  36. Merkel, O., Hamacher, F., Griessl, R., Grabner, L., Schmatz, A., Prutsch, N., Baer, C., Hartmann, T., Simonitsch, I., Plass, C., Turner, S.D., Zenz, T., Greil, R. and Kenner, L. (2015) Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J. Path Aug;236(4):445-56. doi: 10.1002/path.4539.
  37. Turner, S.D., Lamant, L., Kenner, L. and Brugieres, L. (2015) Anaplastic Large Cell lymphoma: biology and clinical application. British Journal of Haematology, 173(3):560-72, doi: 10.1111/bjh.13958. 
  38. Ye X., Shokrollahi K., Rozen W.M., Whitaker I.S.,* and Turner S.D.* (2014) Anaplastic Large Cell Lymphoma (ALCL) and Breast Implants: Breaking down the evidence *joint corresponding authors. Mutation Research – Reviews, 762C:123-132. 
  39. Moti, N., Malcolm, T., Hamoudi, R., Mian, S., Garland, G., Hook, C.E., Burke, G.A.A., Wasik, M., Merkel, O., Kenner, L., Laurenti, E., Dick, J.E. and Turner, S.D. (2014) Anaplastic Large Cell Lymphoma stem cells possess a gene expression profile reflective of an early thymic progenitor pointing to a primitive cell of origin. Oncogene, Apr 2;34(14):1843-52. doi: 10.1038/onc.2014.112 
  40. Laimer, D., Dolznig, H., Kollmann, K., Vesely, P.W., Schlederer, M., Merkel, O., Schiefer, A., Hassler, M.R., Heider, S., Amenitsch, L., Thallinger, C., Staber, P.B., Simonitsch-Klupp, I., Artaker, M., Lagger, S., Turner, S.D., Pileri, S., Piccaluga, P.P., Valent, P., Messana, K., Landra, I., Weichhart, T., Knapp, S., Shehata, M., Todaro, M., Sexl, V., Höfler, G., Piva, R., Medico, E., Riggeri, B.A., Cheng, M., Eferl, R., Egger, G., Penninger, J.M., Jaeger, U., Moriggl, R., Inghirami, G. and Kenner, L. (2012) Identification of PDGFR blockade as a rational and highly effective therapy for NPM-ALK driven lymphomas. Nature Medicine 18(11):1699-704 
  41. Martinelli, P., Bonetti, P., Sironi, C., Pruneri, G., Fumagalli, C., Raviele, PR., Volorio, S., Pileri, S., Chiarle, R., Khoramian Tusi, B., McDuff, F.K.E., Turner, S.D., Inghirami, G., Pelicci, P.G. and Colombo, E. (2011) The lymphoma-associated NPM-ALK oncogene elicits a p16INKa/pRb-dependent tumour-suppressive pathway. Blood 117(24):6617-26. 
  42. Merkel, O., Hamacher, F., Laimer, D., Scheideler, M., Trajanoski, Z., Egger, G., Turner, SD., Greil, R. and Kenner, L. (2010) Diacritic and functionally active microRNAs in both ALK+ and ALK- ALCL. PNAS 107(37):16228-33 
  43. Youssif, C., Goldenbogan J., Hamoudi R., Viskaduraki M., Bacon, CM, Burke, A.A and Turner S.D. (2009) Genomic profiling of pediatric ALK-positive Anaplastic Large Cell Lymphoma – a Children’s Cancer and Leukaemia Group study. Genes Chromosomes and Cancer 48(11):1018-26 
  44. Cui Y., Kerby A., McDuff F.K.E. and Turner S.D. (2009) NPM-ALK modulates the p53 tumour suppressor pathway in a JNK and PI 3-Kinase dependent manner: MDM-2 is a potential therapeutic target for the treatment of ALK-expressing malignancies. Blood. 113(21):5217-5227. 
  45. Turner S.D., Yeung D., Hadfield K., Cook S.J. and Alexander D.R. (2007) The NPM- ALK Tyrosine Kinase Mimics TCR Signalling Pathways Inducing NFAT and AP-1 by Ras-Dependent Mechanisms. Cellular Signaling. 19(4):740-47.
  46. Turner S.D., Tooze R.M., Macklennan K., Alexander D.R. (2003) Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 22:7750-7761.
Other publications: 
  1. Final Opinion on the safety of breast implants in relation to anaplastic large cell lymphoma. SCHEER WG on the safety of breast implants in relation to anaplastic large cell lymphoma (BIA-ALCL). SCHEER members: Wim H De Jong (Chair), Demosthenes Panagiotakos (Rapporteur), Ana Proykova, Theodoros Samaras. External experts: Mark Clemens, Daphne De Jong, Ingrid Hopper, Hinne Rakhorst, Fabio Santanelli di Pompeo, Suzanne D. Turner. On request from: European Commission, Adopted on: 26 March 2021 https://ec.europa.eu/health/scientific_committees/scheer/opinions_en?fbc...
  2. Turner, S.D. (2019) Anaplastic Large Cell Lymphoma: chapter in Non-Hodgkin Lymphoma in Childhood and Adolescence, Springer International Publishing DOI: 10.1007/978-3-030-11769-6, eBook ISBN: 978-3-030-11769-6, Hardcover ISBN:978-3-030-11768-9
  3. Turner, S.D. (2019) Commentary on: Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia: A Longitudinal Study of Implant and Other Related Risk Factors. Aesthetic Surgery Journal, DOI10.1093/asj/sjz371 [IF1.84].
  4. Turner, S.D. (2019) Commentary on: Deposition of Host Matrix Proteins on Breast Implant Surfaces Facilitates Staphylococcus Epidermidis Biofilm Formation: In Vitro Analysis. Aesthetic Surgery Journal, pii: sjz144. doi: 10.1093/asj/sjz144 
  5. Turner, S.D. and Wright, P. (2019) Commentary on: Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthetic Surgery Journal, 1-2, DOI: 10.1093/asj/sjz025
  6. Turner, S.D. (2019) Commentary on: Anaplastic Large Cell Lymphoma of the Breast Arising in a Burn Cicatrix. Aesthetic Surgery Journal, DOI10.1093/asj/sjz285
  7. Turner, S.D. (2019) Commentary on: Deposition of Host Matrix Proteins on Breast Implant Surfaces Facilitates Staphylococcus Epidermidis Biofilm Formation: In Vitro Analysis. Aesthetic Surgery Journal, pii: sjz144. doi: 10.1093/asj/sjz144 
  8. Turner, S.D. (2019) Anaplastic Large Cell Lymphoma, book chapter in INTech Open access Peripheral T cell lymphoma, DOI: 10.5772/intechopen.81382

Teaching and Supervisions

Teaching: 
  1. Organiser Part 1B Biology of Disease medical and veterinary science tripos/Natural sciences tripos (MVST/NST) course October 2014-2019 
  2. Cambridge University, Department of Pathology Natural Sciences Tripos Part II ‘modelling cancer in vivo
  3. Cambridge University, Department of Pathology Part 1B (second year) Biology of Disease course x 3 lectures on cancer biology to ~450 students
  4. Lecture on paediatric cancer research to the MRes CRUK Cambridge cancer programme
  5. Organiser Part 1B histopathology practical classes October 2013-October 2015
  6. Leading and demonstrating the part 1B natural science tripos and MVST practicals and problem-solving exercises (histology based; immunology, cancer and other diseases), Cambridge University.
Research supervision: 

Current and past graduate students

Name

Funding body/Course

Years of study

Position on leaving my lab

Alisha Burman

NIHR academic clinical fellow

2021

Clinical training

Emily James

MRC DTP

2021-2025

N/A

Lucy Hare

CRUK Cambridge Centre clinical PhD fellowship

2020-2023

N/A

Mun Liew

Children’s Cancer and Leukaemia Group

2018-2021

N/A

Jamie Matthews

Alex Hulme Foundation PhD

2017-2022

N/A

Nina Prokoph

EU Marie-Curie ALKATRAS ITN

2016-2020

PostDoc at DKFZ German Cancer Research Center and Heidelberg University Hospital

Stephen Ducray

EU Marie-Curie ALKATRAS ITN

2016-2020

Strategy and Business Consulting for Bayer's R&D sector

Hugo Larose

Department Centenary Fund PhD Studentship

2015-2019

Pharmaceutical consulting

Sorcha Forde

Alex Hulme Foundation PhD

2014-2018

Pharmaceutical Consulting

Liam Lee

CRUK PhD

2013-2017

Merck – Director of medical affairs, oncology

Camilla Fairbairn

BBSRC PhD

2013-2017

Postdoc., Black Belt Therapeutics

Gavin Garland

BBSRC PhD

2010-2014

Research Associate, MRC Toxicology Unit, Leicester

Timothy Malcolm

LLR PhD

2009-2013

Postdoc., Kudos, Cambridge

Bola Hanna

MSc, University of Ulm, Germany

2011

PhD, Heidelberg

Naushad Moti

Pakistani Higher Education Commission PhD

2008-2012

Research Associate, Duke-NUS, Singapore, Prof. David Virshup

Suzanne Rigby

MRC PhD

2006-2009

Senior Scientist, GSK

Fiona McDuff

Wellcome Trust PhD

2006-2009

Research Associate, University of Cambridge, Prof. Gerard Evan

Catrin Youssif

MSc, University of Vienna, Austria

2008-2009

PhD, Barcelona

Other Professional Activities

  1. Chair of graduate education of the department of pathology
  2. Fellow and Tutor Hughes Hall
  3. Executive committee member and co-lead paediatric programme, Cambridge Cancer Centre
  4. Coordinator ALKATRAS Marie Curie Innovative Training Network (www.alkatras.erialcl.net)
  5. Biological studies lead, NCRI paediatric lymphoma clinical studies sub-group
  6. Chair of the European Research Initiative for ALK-related malignancies (ERIA; www.erialcl.net)
  7. Co-chair European Inter-group for Childhood Non-Hodgkin Lymphoma (EICNHL)
  8. Member the MHRA plastics, reconstructive and aesthetic surgery (PRASEAG) committee and the European Commission’s Scientific committee on Health, Environmental and Emerging Risks (SCHEER) working group on breast implants and cancer
  9. Member of the grant panel of the Swedish Research Council’s medicine and health review panel
  10. Member of the international grant panel of the World Cancer Research Fund
  11. Member of the scientific meetings committee of the International Society for Paediatric Oncology (SIOP) Eurpoean arm
  12. Scientific advisor to the Alex Hulme Foundation and Francesca Richardson Trust
  13. Chief scientific advisor to Melior Capital Management 2020-
  14. Invited member of the Continuous Update Project (CUP) mechanisms Expert Committee, Worldwide Cancer Research Fund Network, 1st February 2022 - 31st January 2025.
  15. American Association of Plastic Surgeons 2022 Expert Consensus Panel on BIA-ALCL, 2022
  16. Children’s Cancer and Leukaemia Group (CCLG) Biological Studies Steering Group (BSSG)
  17. Invited member of the University of Padova PhD collegium
Professor of Cellular and Molecular Tumour Biology
Division of Cellular and Molecular Pathology
Dr Suzanne D Turner

Contact Details

Division of Cellular and Molecular Pathology
Lab Block Level 3
Box 231
Addenbrooke's Hospital
Cambridge
CB2 0QQ
+44 (0) 1223 762655 / 31699
Takes PhD students
Available for consultancy